Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:
- Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
- Helping pets live longer, healthier lives through advanced veterinary products.
- Improving food safety standards globally.
Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.
Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.
Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.
Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.
Elanco Animal Health reported Q4 2022 revenue of $988 million, an 11% decline year-over-year, with a net loss of $54 million. For the full year, total revenue was $4,418 million, down 7% from 2021. Adjusted net income for Q4 was $95 million, with an adjusted EBITDA margin of 17.6%. The company has guided for 2023 revenues between $4,280 million and $4,400 million and a reported net loss of $157 million to $109 million. Elanco is pursuing FDA approvals for new products expected in early 2024. The company faces ongoing competitive pressures but anticipates sales growth from innovation and pricing.
Elanco Animal Health (NYSE: ELAN) announced the appointment of Tim Bettington as the executive vice president of Corporate Strategy and Market Development, effective March 20. Bettington's role will focus on corporate strategy and market development, particularly in preparing for a significant innovation period and driving growth initiatives for 2025 and beyond. He brings over 25 years of experience in animal health, previously serving at Zoetis and Boehringer Ingelheim. CEO Jeff Simmons emphasized the addition strengthens Elanco's leadership, aimed at enhancing market share and executing successful product launches amidst an exciting pipeline.
Elanco Animal Health Incorporated (NYSE: ELAN) will release its fourth quarter and full year 2022 financial results on February 21, 2023. A conference call is scheduled for 8:00 a.m. eastern time that day, where the company will discuss its performance with investors and media. The call will be accessible via a live webcast posted on Elanco's website, with a replay available shortly after. Elanco is committed to providing innovative animal health products and services aimed at improving the health of farm animals and pets, with nearly 70 years of experience in the field.
Elanco Animal Health (NYSE: ELAN) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 12:45 p.m. ET. The company will be represented by Jeff Simmons, president and CEO, who will address analyst questions during the event.
A live audio webcast will be accessible in the 'Events and Presentations' section of Elanco’s investor website, with a replay available for 30 days.
Elanco Animal Health (NYSE:ELAN) announces FDA approval for Bexacat™ (bexagliflozin tablets), the first oral medication improving glycemic control in diabetic cats. Approximately 600,000 cats in the U.S. are diagnosed with diabetes, with 125,000 untreated due to insulin's complexities. Bexacat offers a non-insulin, once-daily treatment, enhancing convenience for pet owners. In pivotal studies, 83% of treated cats showed improvement by day 56. Bexacat is expected to be available by Q1 2023, enriching Elanco's feline health portfolio alongside other innovative products.
Elanco Animal Health (NYSE: ELAN) announced its participation in the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022. CEO Jeff Simmons will engage in a fireside chat at 8:50 a.m. Eastern time. A live audio webcast will be accessible via the company’s investor website, with a replay available for 90 days post-event. Elanco, a leader in animal health for nearly 70 years, focuses on innovative solutions for farm animals and pets, committed to enhancing animal health and community impact.
Elanco Animal Health reported Q3 2022 results with revenues of $1,028 million, a 9% decline from last year. Despite challenges, adjusted EPS rose 5% to $0.20. A net loss of $49 million was recorded, improving from $104 million in Q3 2021. The company updated its full-year guidance, forecasting revenue between $4,385 million and $4,430 million. Significant foreign exchange impacts are anticipated, with a loss of around $225 million. Elanco expects five blockbuster product approvals by mid-2024, including a parasiticide and a monoclonal antibody for canine parvovirus.
Elanco Animal Health Incorporated (NYSE: ELAN) will publish its third quarter 2022 financial results on November 8, 2022. Following this, a conference call with investors and media is scheduled for 8:00 a.m. ET to discuss the company’s performance in detail. Participants can access the live webcast through the company's investor relations website. Elanco aims to innovate and deliver products for animal health, enhancing the welfare of animals and providing value across the animal health ecosystem.
Elanco Animal Health (NYSE: ELAN) announced that
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022. Jeff Simmons, the president and CEO, is scheduled for a fireside chat at 2:50 p.m. Eastern time.
A live audio webcast of the event will be accessible via the company’s investor website, with a replay available for 90 days.
FAQ
What is the current stock price of Elanco Animal Health Incorporated (ELAN)?
What is the market cap of Elanco Animal Health Incorporated (ELAN)?
What is Elanco Animal Health's core mission?
In how many countries does Elanco operate?
What recent collaborations has Elanco engaged in?
What is the significance of Elanco's partnership with Athian?
What are some of Elanco's notable products?
How is Elanco addressing sustainability in animal farming?
What financial goals has Elanco set for 2024?
How does Elanco contribute to food safety?
What is Elanco's approach to innovation?
How does Elanco support the health and wellness of pets?
